{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:40:33Z","timestamp":1767069633523,"version":"3.44.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ajog.2017.12.221","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T12:34:30Z","timestamp":1514291670000},"page":"431.e1-431.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women"],"prefix":"10.1016","volume":"218","author":[{"given":"Shreeya","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Legood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-1732","authenticated-orcid":false,"given":"Usha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-5057","authenticated-orcid":false,"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.12.221_bib1","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajog.2017.12.221_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.12.221_bib3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.12.221_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/gim.2016.182","article-title":"Population screening for BRCA1\/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral","volume":"19","author":"Lieberman","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.ajog.2017.12.221_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-generation DNA sequencing","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat Biotechnol"},{"year":"2017","series-title":"Demographics of Judaism","key":"10.1016\/j.ajog.2017.12.221_bib6"},{"key":"10.1016\/j.ajog.2017.12.221_bib7","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1136\/jmg.2004.029785","article-title":"BRCA1:185delAG found in the San Luis Valley probably originated in a Jewish founder","volume":"42","author":"Makriyianni","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ajog.2017.12.221_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/hmg\/7.5.801","article-title":"The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim","volume":"7","author":"Bar-Sade","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajog.2017.12.221_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000484800","article-title":"Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?","volume":"5","author":"Bar-Sade","year":"1997","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ajog.2017.12.221_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib11","unstructured":"Drummond M, Sculpher M, Claxton K, Stoddart\u00a0G, Torrance G. Methods for the economic\u00a0evaluation of health care programmes. Oxford\u00a0(United Kingdom): Oxford University Press."},{"key":"10.1016\/j.ajog.2017.12.221_bib12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.221_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2017.12.221_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1258\/mi.2010.010023","article-title":"Compliance with estrogen hormone replacement therapy after oophorectomy: a prospective study","volume":"16","author":"Read","year":"2010","journal-title":"Menopause international"},{"year":"2008","series-title":"Guide to the methods of technology appraisal","key":"10.1016\/j.ajog.2017.12.221_bib17"},{"key":"10.1016\/j.ajog.2017.12.221_bib18","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"year":"2013","series-title":"NHS Reference Costs 2012\u20132013","key":"10.1016\/j.ajog.2017.12.221_bib19"},{"year":"2011","series-title":"Unit costs of health and social care 2011","author":"Curtis","key":"10.1016\/j.ajog.2017.12.221_bib20"},{"key":"10.1016\/j.ajog.2017.12.221_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjsurg.2003.11.039","article-title":"Clinical profile of breast cancer in Arab and Jewish women in the Jerusalem area","volume":"188","author":"Nissan","year":"2004","journal-title":"Am J Surg"},{"key":"10.1016\/j.ajog.2017.12.221_bib22","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"year":"2014","series-title":"Surviellance, Epidemiology, and End Results. Cancer stat facts: female breast cancer. USA: National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program","key":"10.1016\/j.ajog.2017.12.221_bib23"},{"year":"2014","series-title":"Surviellance, Epidemiology, and End Results. Cancer stat facts: ovary cancer","key":"10.1016\/j.ajog.2017.12.221_bib24"},{"year":"2017","series-title":"Lifetable for females in the UK: Office of National Statitics, 2015 (vol 2017)","key":"10.1016\/j.ajog.2017.12.221_bib25"},{"key":"10.1016\/j.ajog.2017.12.221_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","article-title":"Prognosis of BRCA-associated breast cancer: a summary of evidence","volume":"119","author":"Bordeleau","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2017.12.221_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","volume":"357","author":"Rennert","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.12.221_bib28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.12.221_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","article-title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","volume":"140","author":"Kotsopoulos","year":"2016","journal-title":"Gynecol Oncol"},{"year":"2016","series-title":"Surviellance, Epidemiology, and End Results. Relative survival rates by year of diagnosis, CSR 1975\u20132013","key":"10.1016\/j.ajog.2017.12.221_bib30"},{"key":"10.1016\/j.ajog.2017.12.221_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"year":"2009","series-title":"Clinical Guideline (CG81)\u2014advanced breast cancer: diagnosis and treatment","key":"10.1016\/j.ajog.2017.12.221_bib32"},{"key":"10.1016\/j.ajog.2017.12.221_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-009-0373-6","article-title":"Breast cancer-related preferences among women with and without BRCA mutations","volume":"119","author":"Grann","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2017.12.221_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1258\/mi.2008.008016","article-title":"Prophylactic oophorectomy in pre-menopausal women and long term health\u2014a review","volume":"14","author":"Shuster","year":"2008","journal-title":"Menopause Int"},{"key":"10.1016\/j.ajog.2017.12.221_bib36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","article-title":"Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers","volume":"125","author":"Grann","year":"2011","journal-title":"Breast Cancer Res Treat"},{"year":"2017","series-title":"Developing NICE guidelines: the manual","key":"10.1016\/j.ajog.2017.12.221_bib37"},{"article-title":"Social value judgements: principles for the development of NICE guidance","year":"2008","series-title":"(NICE) NIfHaCE","key":"10.1016\/j.ajog.2017.12.221_bib38"},{"key":"10.1016\/j.ajog.2017.12.221_bib39","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn't it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajog.2017.12.221_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.12.221_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.12.221_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/cge.12149","article-title":"Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers","volume":"85","author":"Laitman","year":"2014","journal-title":"Clin Genet"},{"key":"10.1016\/j.ajog.2017.12.221_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1467-985X.00283","article-title":"A\u00a0Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer","volume":"166","author":"Cooper","year":"2003","journal-title":"J\u00a0R Stat Soc Series A (Statistics in Society)"},{"key":"10.1016\/j.ajog.2017.12.221_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2017.12.221_bib45","doi-asserted-by":"crossref","first-page":"578.e1","DOI":"10.1016\/j.ajog.2017.06.038","article-title":"Cost-effectiveness of population based BRCA\u00a0testing with varying Ashkenazi Jewish ancestry","volume":"217","author":"Manchanda","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.221_bib46","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","article-title":"Panel testing for familial breast cancer: calibrating the tension between research and clinical care","volume":"34","author":"Thompson","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-011-1433-2","article-title":"Relative contributions of BRCA1 and BRCA2 mutations to \u201ctriple-negative\u201d breast cancer in Ashkenazi women","volume":"129","author":"Comen","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2017.12.221_bib48","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1200\/JCO.2012.44.5635","article-title":"Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations","volume":"30","author":"Tung","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib50","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/1055-9965.EPI-10-1325","article-title":"Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort","volume":"20","author":"Brinton","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2017.12.221_bib51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00001648-199011000-00010","article-title":"Cigarette smoking and the risk of natural menopause","volume":"1","author":"Midgette","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajog.2017.12.221_bib52","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/sj.bjc.6605965","article-title":"Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition","volume":"103","author":"Tsilidis","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2017.12.221_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.12.221_bib54","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv217","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Chai","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"year":"2016","series-title":"GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 online analysis > prediction","key":"10.1016\/j.ajog.2017.12.221_bib56"},{"key":"10.1016\/j.ajog.2017.12.221_bib57","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"year":"2015","series-title":"Cancer incidence for common cancers. The 10 most common cancers in females, UK, 2012","key":"10.1016\/j.ajog.2017.12.221_bib58"},{"key":"10.1016\/j.ajog.2017.12.221_bib59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated\u00a0with risk-reducing salpingo-oophorectomy\u00a0in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.12.221_bib60","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ygyno.2015.06.020","article-title":"Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy","volume":"138","author":"Garcia","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib61","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial\u00a0of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib62","unstructured":"British National Formulary. British National Formulary 67. London (United Kingdom): BMJ\u00a0Group, and the Pharmaceutical Press (Royal Pharmaceutical Society of Great Britain); 2014."},{"key":"10.1016\/j.ajog.2017.12.221_bib63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/WHE.09.49","article-title":"Costs of hormonal and nonhormonal prescription medications for hot flashes","volume":"5","author":"Williams-Frame","year":"2009","journal-title":"Womens Health (Lond)"},{"year":"2011","series-title":"Ovarian cancer: the recognition and initial management of ovarian cancer. (vol CG122)","key":"10.1016\/j.ajog.2017.12.221_bib64"},{"key":"10.1016\/j.ajog.2017.12.221_bib65","unstructured":"Incisive Health and Cancer Research UK. Saving lives, averting costs. An analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer. London, United Kingdom: Cancer Research UK; 2014."},{"year":"2008","series-title":"End of life care","key":"10.1016\/j.ajog.2017.12.221_bib66"},{"year":"2013","series-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the US Preventive Services Task Force recommendation","author":"Nelson","key":"10.1016\/j.ajog.2017.12.221_bib67"},{"key":"10.1016\/j.ajog.2017.12.221_bib68","doi-asserted-by":"crossref","first-page":"v","DOI":"10.3310\/hta15340","article-title":"The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation","volume":"15","author":"Robertson","year":"2011","journal-title":"Health Technol Assess"},{"year":"2013","series-title":"Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer","key":"10.1016\/j.ajog.2017.12.221_bib69"},{"year":"2009","series-title":"Early and locally advanced breast cancer: diagnosis and treatment. NICE Clinical Guideline, CG80","key":"10.1016\/j.ajog.2017.12.221_bib70"},{"key":"10.1016\/j.ajog.2017.12.221_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.22341","article-title":"Hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention in the United States are substantially higher than Medicare payments","volume":"38","author":"Afana","year":"2015","journal-title":"Clin Cardiol"},{"year":"2010","series-title":"Breast Screening Programme, England, 2008\u20132009","author":"Waldron","key":"10.1016\/j.ajog.2017.12.221_bib72"},{"year":"2016","series-title":"Breast cancer screening guidelines for women","key":"10.1016\/j.ajog.2017.12.221_bib73"},{"key":"10.1016\/j.ajog.2017.12.221_bib74","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1053\/ejso.2002.1279","article-title":"Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB[O]C) or a proven BRCA1 and BRCA2 germ-line mutation","volume":"28","author":"Contant","year":"2002","journal-title":"Eur J Surg Oncol"},{"year":"2009","series-title":"National costing report: early and locally advanced breast cancer\/advanced breast cancer","key":"10.1016\/j.ajog.2017.12.221_bib75"},{"key":"10.1016\/j.ajog.2017.12.221_bib76","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/bjc.2012.30","article-title":"Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006\u20132009","volume":"106","author":"Lyratzopoulos","year":"2012","journal-title":"Br J Cancer"},{"year":"2012","series-title":"Breast cancer incidence statistics UK 2009\u20132011, breast cancer (C50). Average number of new cases per year and age-specific incidence rates, females, UK, 2009\u20132011","key":"10.1016\/j.ajog.2017.12.221_bib77"},{"year":"2008","series-title":"Registrations of cancer diagnosed in 2006, England. Cancer statistics registrations, the Office for National Statistics","key":"10.1016\/j.ajog.2017.12.221_bib78"},{"key":"10.1016\/j.ajog.2017.12.221_bib79","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1055-9965.EPI-11-1196","article-title":"Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined","volume":"21","author":"Heijnsdijk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2017.12.221_bib80","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1200\/JCO.2008.19.8424","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer","volume":"27","author":"Anderson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.12.221_bib81","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/cncr.21359","article-title":"Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies","volume":"104","author":"Gennari","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2017.12.221_bib82","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2005.04.3273","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials","volume":"24","author":"Wapnir","year":"2006","journal-title":"J\u00a0Clin Oncol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817327205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817327205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:19:32Z","timestamp":1757589572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817327205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0002937817327205"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.12.221","relation":{},"ISSN":["0002-9378"],"issn-type":[{"type":"print","value":"0002-9378"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.12.221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}